Back to Search Start Over

Impact of Initial Management on Disease Evolution in Vogt-Koyanagi-Harada Syndrome: A Retrospective Cohort of 50 Patients.

Authors :
Fauquier A
Barba T
Hot A
Sève P
Elbany S
Blanche P
Monnet D
Brézin A
Terrier B
Durel CA
Source :
Ocular immunology and inflammation [Ocul Immunol Inflamm] 2024 May; Vol. 32 (4), pp. 402-406. Date of Electronic Publication: 2023 May 04.
Publication Year :
2024

Abstract

Purpose: The study aims to determine the impact of initial management in Vogt-Koyanagi-Harada syndrome (VKHS).<br />Methods: Patients diagnosed with a VKHS between January 2001 and December 2020 in two French tertiary centers were included in a retrospective study.<br />Results: Fifty patients were included with a median duration of follow-up of 29.8 months. All patients received oral prednisone after methylprednisolone in all but four of them. Five patients received at least one associated immunosuppressive therapy (IST) within the first 6 months and 26 patients received IST during the entire follow-up period. Twenty-eight patients presented at least one relapse at a median of 5.4 months from diagnosis. Multivariate analyses demonstrated a significant association between relapse and delayed treatment (>26 days) (HR = 3.69, CI95% 1.30-10.47, p = .01), whereas no association was observed between relapse and the number of corticosteroid pulses at initial management.<br />Conclusion: An early corticosteroid treatment within the first 26 days of symptoms decreased the relapse rate.

Details

Language :
English
ISSN :
1744-5078
Volume :
32
Issue :
4
Database :
MEDLINE
Journal :
Ocular immunology and inflammation
Publication Type :
Academic Journal
Accession number :
37141529
Full Text :
https://doi.org/10.1080/09273948.2023.2206485